Combination therapy for elderly or unfit adults with acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs for treating newly diagnosed AML in older or frailer patients. The goal is to see if this combination is safe and effective, providing a gentler option for those who cannot handle standard intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of acute myeloid leukemia (AML), a type of blood cancer.
- You have not had any prior treatment for AML (except hydroxyurea, which is sometimes used to lower very high white blood cell counts).
- You are either 75 years or older, or you are between 18 and 74 and have health conditions that make standard intensive chemotherapy risky.
- You are generally able to care for yourself (able to be up and about, even if you need rest).
- You are expected to live at least 3 more months.
- If you can have children, you agree to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different combinations of chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). One combination uses newer targeted drugs, while the other is a standard treatment. The goal is to see which approach works better.
This study compares two combinations of chemotherapy drugs to see which one works better for people with certain types of acute myeloid leukemia (AML) or a high-risk bone marrow disorder called MDS. The goal is to find a treatment that may help control the disease and improve quality of life.
This trial tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor to treat newly diagnosed AML in people who aren't strong enough for standard chemo. The goal is to see if this combo can help control the leukemia with fewer side effects.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.